Jazz Pharmaceuticals is still well oriented and is going to new highs.

Regarding the fundamentals, the firm is financially healthy with no financial leverage because of a cash surplus expected for 2013. Moreover the group has a very high operating margin at 56.7% for 2013, sign of a valuable business.

Graphically, the security is up 29% since the 1st January. It seems able to continue this uptrend supported by moving averages and will soon test the USD 70.8 mid-term resistance. We anticipate a crossing of this level, given the upward orientation of the stock in the medium and long term.

Exceeding the technical line at USD 70.9 would point to ambitious upward targets. In this case, market participants could buy this stock with an initial target of USD 76.5. If investors reduce long-side exposure for profit-taking, a bearish trend would happen below USD 68.5 and so this strategy would be invalidated.